IGMS IGM Biosciences Inc.

46.48
+3.48  (+8%)
Previous Close 43
Open 41.13
Price To Book 5.57
Market Cap 1,419,308,586
Shares 30,535,899
Volume 110,717
Short Ratio
Av. Daily Volume 147,569
Stock charts supplied by TradingView

NewsSee all news

  1. IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    - Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin's lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Company to host conference call today

  2. IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020

    MOUNTAIN VIEW, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that

  3. IGM Biosciences to Present at Two Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that

  4. IGM Biosciences to Present at Two Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced that Fred

  5. IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis

    MOUNTAIN VIEW, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced the appointment of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 initial data due 2H 2020.
IGM-2323
Relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL)

Latest News

  1. IGM Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

    - Initial data from Phase 1 trial of IGM-2323 in relapsed/refractory non-Hodgkin's lymphoma expected in the second half of 2020 - - IND filing for IGM-8444 planned in 2020 - - Company to host conference call today

  2. IGM Biosciences to Announce Fourth Quarter and Year-end 2019 Financial Results and Host Conference Call and Webcast on March 26, 2020

    MOUNTAIN VIEW, Calif., March 19, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that

  3. IGM Biosciences to Present at Two Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., March 04, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that

  4. IGM Biosciences to Present at Two Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced that Fred

  5. IGM Biosciences Appoints Eric Humke, M.D., Ph.D., as Vice President, Clinical Development, Apoptosis

    MOUNTAIN VIEW, Calif., Jan. 07, 2020 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a global leader in the research and development of engineered therapeutic IgM antibodies, today announced the appointment of

  6. IGM Biosciences to Present at Three Upcoming Investor Conferences

    MOUNTAIN VIEW, Calif., Nov. 12, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of

  7. IGM Biosciences Announces Third Quarter 2019 Financial Results

    MOUNTAIN VIEW, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of

  8. IGM Biosciences Initiates First-in-Human Phase 1 Clinical Trial of IGM-2323 for the Treatment of Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

    MOUNTAIN VIEW, Calif., Oct. 02, 2019 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ:IGMS), a biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients,